MLTX Investors Offered Leadership Role in MoonLake Immunotherapeutics Securities Fraud Class Action

A national shareholder‑rights litigation firm, The Schall Law Firm, is inviting investors of MoonLake Immunotherapeutics (NASDAQ: MLTX) to step forward as lead plaintiffs in a proposed class‑action case — alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b‑5. The action targets statements by MoonLake between March 10, 2024 and September 29, 2025, during which the company reportedly misrepresented its clinical‑trial results for its drug candidate sonelokimab (SLK), claiming superior performance over other monoclonal antibodies despite lacking proof. When a Phase 3 trial revealed what analysts called a “disastrous result”, the company’s shares plunged nearly 90 percent, harming investors who relied on the prior statements. Interested shareholders have until December 15, 2025 to contact the firm free‑of‑charge to discuss their potential role and rights. #MoonLake #SecuritiesFraud #ShareholderRights #MLTX #SlimScan #GrowthStocks #CANSLIM